Glycyrrhizic acid attenuates sorafenib resistance by inducing ferroptosis via targeting mTOR signaling in hepatocellular carcinoma

References

• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314. doi:10.1016/S0140-6736(18)30010-2.
   PubMed Web of Science ®Google Scholar
• Nagaraju GP, Dariya B, Kasa P, et al. Epigenetics in hepatocellular carcinoma. Semin Cancer Biol. 2022;86(Pt 3):622–632. doi:10.1016/j.semcancer.2021.07.017.
   PubMedGoogle Scholar
• Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):7.
   PubMed Web of Science ®Google Scholar
• Ganesan P, Kulik LM. Hepatocellular carcinoma: new developments. Clin Liver Dis. 2023;27(1):85–102. doi:10.1016/j.cld.2022.08.004.
   PubMed Web of Science ®Google Scholar
• Tang WW, Chen Z, Zhang W, Cheng Y, Zhang B, Wu F. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther. 2020;5(1):87.
   PubMed Web of Science ®Google Scholar
• Xia S, Pan Y, Liang Y, et al. The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma. EBioMedicine. 2020;51:102610. doi:10.1016/j.ebiom.2019.102610.
   PubMed Web of Science ®Google Scholar
• Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22(4):266–282. doi:10.1038/s41580-020-00324-8.
   PubMed Web of Science ®Google Scholar
• Wu X, Li Y, Zhang S, et al. Ferroptosis as a novel therapeutic target for cardiovascular disease. Theranostics. 2021;11(7):3052–3059. doi:10.7150/thno.54113.
   PubMed Web of Science ®Google Scholar
• Chen X, Kang R, Kroemer G. Tang ferroptosis in infection, inflammation, and immunity. J Exp Med. 2021;218(6): e20210518.
   Web of Science ®Google Scholar
• Tang D, Chen X, Kang R, et al. Ferroptosis: molecular mechanisms and health implications. Cell Res. 2021;31(2):107–125. doi:10.1038/s41422-020-00441-1.
   PubMed Web of Science ®Google Scholar
• Ozkan E, Bakar-Ates F. Ferroptosis: a trusted ally in combating drug resistance in cancer. Curr Med Chem. 2022;29(1):41–55. doi:10.2174/0929867328666210810115812.
   PubMed Web of Science ®Google Scholar
• Friedmann Angeli JP, Krysko DV, Conrad M. Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. Nat Rev Cancer. 2019;19(7):405–414. doi:10.1038/s41568-019-0149-1.
   PubMed Web of Science ®Google Scholar
• Chen K, Yang R, Shen F-Q, et al. Advances in pharmacological activities and mechanisms of glycyrrhizic acid. Curr Med Chem. 2020;27(36):6219–6243. doi:10.2174/0929867325666191011115407.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang L, Luo R, et al. Glycyrrhizic acid against Mycoplasma gallisepticum-induced inflammation and apoptosis through suppressing the MAPK pathway in chickens. J Agric Food Chem. 2022;70(6):1996–2009. doi:10.1021/acs.jafc.1c07848.
   PubMed Web of Science ®Google Scholar
• Zeeshan M, Ali H, Khan S, et al. Glycyrrhizic acid-loaded pH-sensitive poly-(lactic-co-glycolic acid) nanoparticles for the amelioration of inflammatory bowel disease. Nanomedicine (Lond). 2019;14(15):1945–1969. doi:10.2217/nnm-2018-0415.
   PubMed Web of Science ®Google Scholar
• Chen Y, Qu L, Li Y, et al. Glycyrrhizic acid alleviates lipopolysaccharide (LPS)-induced acute lung injury by regulating Angiotensin-Converting enzyme-2 (ACE2) and caveolin-1 signaling pathway. Inflammation. 2022;45(1):253–266. doi:10.1007/s10753-021-01542-8.
   PubMed Web of Science ®Google Scholar
• Pastorino G, Cornara L, Soares S, et al. Liquorice (glycyrrhiza glabra): a phytochemical and pharmacological review. Phytother Res. 2018;32(12):2323–2339. doi:10.1002/ptr.6178.
   PubMedGoogle Scholar
• Cao R, Li Y, Hu X, Qiu Y, Li S, Xie Y. Glycyrrhizic acid improves tacrolimus-induced renal injury by regulating autophagy. Faseb j. 2023;37(2):e22749.
   PubMed Web of Science ®Google Scholar
• Tan DD, Tseng HHL, Zhong Z, Wang S, Vong CT. Wang glycyrrhizic acid and its derivatives: promising candidates for the management of type 2 diabetes mellitus and its complications. Int J Mol Sci. 2022;23(19): 10988.
   Web of Science ®Google Scholar
• Hostetler BJ, Uchakina ON, Ban H, et al. Treatment of hematological malignancies with glycyrrhizic acid. Anticancer Res. 2017;37(3):997–1004. doi:10.21873/anticanres.11409.
   PubMed Web of Science ®Google Scholar
• Selyutina OY, Polyakov NE. Glycyrrhizic acid as a multifunctional drug carrier - From physicochemical properties to biomedical applications: a modern insight on the ancient drug. Int J Pharm. 2019;559:271–279. doi:10.1016/j.ijpharm.2019.01.047.
   PubMed Web of Science ®Google Scholar
• Su X, Wu L, Hu M, et al. Glycyrrhizic acid: a promising carrier material for anticancer therapy. Biomed Pharmacother. 2017;95:670–678. doi:10.1016/j.biopha.2017.08.123.
   PubMed Web of Science ®Google Scholar
• Yang J, Xu J, Zhang B, Tan Z, Meng Q, Hua J. Ferroptosis: at the crossroad of gemcitabine resistance and tumorigenesis in pancreatic cancer. Int J Mol Sci. 2021;22(20): 10944.
   Web of Science ®Google Scholar
• Zhang C, Liu X, Jin S, et al. Ferroptosis in cancer therapy: a novel approach to reversing drug resistance. Mol Cancer. 2022;21(1):47. doi:10.1186/s12943-022-01530-y.
   PubMed Web of Science ®Google Scholar
• Guerrero-Zotano A, Mayer IA, Arteaga CL. PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment. Cancer Metastasis Rev. 2016;35(4):515–524. doi:10.1007/s10555-016-9637-x.
   PubMed Web of Science ®Google Scholar
• Liu R, Chen Y, Liu G, et al. PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis. 2020;11(9):797. doi:10.1038/s41419-020-02998-6.
   PubMed Web of Science ®Google Scholar
• Pi M, Kuang H, Yue C, et al. Targeting metabolism to overcome cancer drug resistance: a promising therapeutic strategy for diffuse large B cell lymphoma. Drug Resist Updat. 2022;61:100822. doi:10.1016/j.drup.2022.100822.
   PubMed Web of Science ®Google Scholar
• Popova NV, Jücker M. The role of mTOR signaling as a therapeutic target in cancer. Int J Mol Sci. 2021;22(4):1743. doi:10.3390/ijms22041743.
   PubMed Web of Science ®Google Scholar
• Cheng Q, Chen M, Liu M, et al. Semaphorin 5A suppresses ferroptosis through activation of PI3K-AKT-mTOR signaling in rheumatoid arthritis. Cell Death Dis. 2022;13(7):608. doi:10.1038/s41419-022-05065-4.
   PubMed Web of Science ®Google Scholar
• Yi J, Zhu J, Wu J, et al. Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis. Proc Natl Acad Sci U S A. 2020;117(49):31189–31197. doi:10.1073/pnas.2017152117.
   PubMed Web of Science ®Google Scholar
• Chen H, Qi Q, Wu N, et al. Aspirin promotes RSL3-induced ferroptosis by suppressing mTOR/SREBP-1/SCD1-mediated lipogenesis in PIK3CA-mutant colorectal cancer. Redox Biol. 2022;55:102426. doi:10.1016/j.redox.2022.102426.
   PubMed Web of Science ®Google Scholar